Indivior PLC announced on May 27, 2025, the appointment of Patrick Barry as its new Chief Commercial Officer, with an effective start date of June 2. In this role, Mr. Barry will be responsible for leading the company's commercial growth strategy, execution, and operations.
Barry's appointment is a strategic move as Indivior continues its mission to transform the treatment of opioid use disorder, with SUBLOCADE being its primary growth driver. He will also join Indivior's executive committee.
This leadership addition underscores Indivior's commitment to enhancing its commercial capabilities and accelerating market penetration for its key products.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.